in vitro PHARMACOLOGY 2011 CATALOG - Cerep
in vitro PHARMACOLOGY 2011 CATALOG - Cerep
in vitro PHARMACOLOGY 2011 CATALOG - Cerep
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
218 <strong>in</strong> <strong>vitro</strong> pharmacology <strong>2011</strong> catalog Trpv1 (vr1) 97<br />
❚ assaY lisT & <strong>in</strong>dex<br />
plK3 154<br />
plK4 154<br />
pnMT (phenylethanolam<strong>in</strong>e n-methyltransferase)<br />
180<br />
ppara 81<br />
ppara - agonist radioligand 81<br />
pparg 81<br />
pparg - agonist radioligand 81<br />
ppard 81<br />
pr 80<br />
pr - agonist radioligand 80<br />
prKx 142<br />
Profile design 7<br />
Profil<strong>in</strong>g/screen<strong>in</strong>g services 4<br />
Prok<strong>in</strong>etic<strong>in</strong> 63<br />
proliferation 192<br />
Prostanoid 63<br />
Proteases 167<br />
Prote<strong>in</strong>ase-activated 66<br />
Prote<strong>in</strong>-ser<strong>in</strong>e/threon<strong>in</strong>e k<strong>in</strong>ases 124<br />
Prote<strong>in</strong>-tyros<strong>in</strong>e k<strong>in</strong>ases 108<br />
protocol(s) 204,205<br />
pTh1 62<br />
Pur<strong>in</strong>ergic 67,90,101<br />
pxr - agonist radioligand 82<br />
pYK2 122<br />
[Q]<br />
quotation 208<br />
[R]<br />
radioligand b<strong>in</strong>d<strong>in</strong>g assays 204<br />
raf-1 k<strong>in</strong>ase 150<br />
raf-1/MeK1 151<br />
rara - agonist radioligand 82<br />
RECEPTORS 13,79,83<br />
Relax<strong>in</strong> 68<br />
requested compound <strong>in</strong>formation 208<br />
results report<strong>in</strong>g 211<br />
ret k<strong>in</strong>ase 116<br />
ripK2 151<br />
rocK1 142<br />
rocK2 143<br />
rolipram - antagonist radioligand 176<br />
ron k<strong>in</strong>ase 116<br />
ros k<strong>in</strong>ase 116<br />
rsK1 143<br />
rsK2 143<br />
rsK3 143<br />
RTK (prote<strong>in</strong>-tyros<strong>in</strong>e k<strong>in</strong>ases) 108<br />
rxfp1 68<br />
rxfp1 - agonist radioligand 68<br />
rY3 (ryanod<strong>in</strong>e)- antagonist radioligand 102<br />
[S]<br />
safety profil<strong>in</strong>g ( <strong>in</strong> <strong>vitro</strong>) 4<br />
s 1 p 1 45<br />
s 1 p 2 46<br />
s 1 p 3 46<br />
sample size(s) 209<br />
screen<strong>in</strong>g (high-thtoughput) 4<br />
secret<strong>in</strong> 40<br />
secretion 187,188,190<br />
Ser<strong>in</strong>e proteases 167<br />
Seroton<strong>in</strong> 68,90,101,105<br />
serum-stimulated a7r5 proliferation 192<br />
service agreement 208<br />
sgK1 143<br />
sgK2 144<br />
sgK3 144<br />
shipment <strong>in</strong>structions 210<br />
Sigma 91<br />
sigma 1 - agonist radioligand 91<br />
sigma 2 - agonist radioligand 91<br />
sigma (non-selective) 91<br />
sigma (non-selective)- agonist radioligand 91<br />
siK 136<br />
sirtu<strong>in</strong> 1 (activator effect) 160<br />
sirtu<strong>in</strong> 1(<strong>in</strong>hibitor effect) 160<br />
sirtu<strong>in</strong> 2 160<br />
sirtu<strong>in</strong> 3 161<br />
Sites (<strong>Cerep</strong> sites)<br />
back cover<br />
sK ca - antagonist radioligand 95<br />
smMlcK (MYlK) 136<br />
solvent 208<br />
Somatostat<strong>in</strong> 73<br />
SPECIALIZED CELLULAR ASSAYS 185<br />
Sph<strong>in</strong>gos<strong>in</strong>e 1-phosphate 45,46<br />
spla 2 (bee venom type iii) 178<br />
spla 2 (Type v) 178<br />
src k<strong>in</strong>ase 122<br />
srm k<strong>in</strong>ase 122<br />
sst 1 73<br />
sst 1 - agonist radioligand 73<br />
sst 2 - agonist radioligand 74<br />
sst 4 74<br />
sst 4 - agonist radioligand 74<br />
sst 5 74<br />
sst 5 - agonist radioligand 74<br />
sst (non-selective)- agonist radioligand 73<br />
STANDARD PROFILES 195<br />
standard profiles (sample sizes) 210<br />
standard solubilization process 209<br />
STE (prote<strong>in</strong>-ser<strong>in</strong>e/threon<strong>in</strong>e k<strong>in</strong>ases) 144<br />
Steroid nuclear receptors 79<br />
sTK33 136<br />
strychn<strong>in</strong>e-sensitive - antagonist radioligand 87,99<br />
study <strong>in</strong>itiation 208,211<br />
suggested test<strong>in</strong>g:<br />
- b<strong>in</strong>d<strong>in</strong>g,enzyme & cellular assays 204<br />
- tissue assays 205<br />
–<br />
superoxide o 2 secretion 190<br />
syk 122<br />
[T]<br />
Tace 173<br />
TaK1-Tab1 (Map3K7) 151<br />
TaoK2 (Tao1) 148<br />
target profile design 8<br />
TbK1 155<br />
Tec k<strong>in</strong>ase 122<br />
TESTING CONDITIONS 203<br />
Tgf-b - agonist radioligand 87<br />
Thyrotrop<strong>in</strong> releas<strong>in</strong>g hormone 75<br />
Tie2 k<strong>in</strong>ase 116<br />
tissue assays 43,205<br />
TKL (prote<strong>in</strong>-ser<strong>in</strong>e/threon<strong>in</strong>e k<strong>in</strong>ases) 149<br />
Tnf-a - agonist radioligand 83<br />
Tnf-a secretion (<strong>in</strong>hibitor effect) 189<br />
Tnk1 122<br />
topoisomerase ii 158<br />
Tp (Tx a2 /pgh 2 ) 66<br />
Tp (Tx a2 /pgh 2 )- antagonist radioligand 66<br />
Transduction signal enzymes 181<br />
Transient receptor potential channels 96<br />
TRANSPORTERS 103<br />
Trh 1 75<br />
Trh 1 - agonist radioligand 75<br />
TrKa 116<br />
TrKb 117<br />
TrKc 117<br />
TrpM8 96<br />
Trpv3 97<br />
Tr (Th)- agonist radioligand 82<br />
tryptase 168<br />
Tsh 40<br />
TssK1 136<br />
TssK2 (sTK22b) 136<br />
TTK 155<br />
tubul<strong>in</strong> 183<br />
turnaround time 211<br />
Tx a2 synthetase 178<br />
Txb 2 secretion (<strong>in</strong>hibitor effect) 188<br />
TxK 123<br />
Tyk2 (JTK1) 123<br />
Tyro3/sky k<strong>in</strong>ase 117<br />
tyros<strong>in</strong>e hydroxylase 180<br />
[U]<br />
UlK1 155<br />
UlK2 155<br />
Urotens<strong>in</strong>-II 75<br />
UT 75<br />
UT - agonist radioligand 75<br />
[V]<br />
v 1a 77<br />
v 1a - agonist radioligand 77<br />
v 1b - agonist radioligand 78<br />
v 2 78<br />
v 2 - agonist radioligand 78<br />
Vasoactive <strong>in</strong>test<strong>in</strong>al peptide 75<br />
Vasopress<strong>in</strong> 77<br />
vdr - agonist radioligand 82<br />
vegf - agonist radioligand 88<br />
vegfr k<strong>in</strong>ase 117<br />
vegf-stimulated hUv-ec-c proliferation 193<br />
Voltage-gated channels 93<br />
vpac 1 (vip 1 ) 76<br />
vpac 1 (vip 1 )- agonist radioligand 76<br />
vpac 2 (vip 2 ) 76<br />
vpac 2 (vip 2 )- agonist radioligand 76<br />
[W]<br />
Wee1 k<strong>in</strong>ase 155<br />
WnK2 155<br />
WnK3 156<br />
WnK4 156<br />
[X]<br />
xanth<strong>in</strong>e oxidase/superoxide o 2<br />
–<br />
scaveng<strong>in</strong>g<br />
183<br />
[Y]<br />
Y 1 57<br />
Y 1 - agonist radioligand 56<br />
Y 2 57<br />
Y 2 - agonist radioligand 57<br />
Y 3 57<br />
Yes k<strong>in</strong>ase 123<br />
Y (non-selective)- agonist radioligand 56<br />
[Z]<br />
Zap70 k<strong>in</strong>ase 123<br />
© cerep - art by françoise rio - conception design & execution: cerep/cather<strong>in</strong>e Moreau<br />
pr<strong>in</strong>ted <strong>in</strong> france (december 2010) by imprimerie chirat on fsc/pefc certified paper
Change language